TEL AVIV UNIVERSITY

Researchers from Tel Aviv University identified a protein, Ly6a, that inhibits the immune system's ability to attack tumors. By removing this protein, they restored the immune system's function, even in cancers resistant to current immunotherapies. This discovery opens new paths for innovative cancer treatments.

Researchers at Tel Aviv University discovered a cancer mechanism inhibiting immune response, reversed by UV-induced protein Ly6a. This breakthrough could lead to innovative immunotherapies for cancers resistant to current treatments.

Researchers at Tel Aviv University discovered a cancer mechanism inhibiting immune response, reversed by UV-induced protein Ly6a, potentially leading to new immunotherapy treatments for resistant tumors.

Pathology faces a crisis due to increasing demand and pathologist shortage, impacting healthcare delivery and patient outcomes. AI offers a solution by enhancing efficiency and accuracy in lab diagnostics, mimicking pathologists' diagnostic approach with precision. However, AI should complement, not replace, human expertise to avoid skill erosion and outdated data. Proper integration of AI can elevate diagnostic standards, improve patient care, and navigate modern healthcare complexities.

New funding from FDA enables researchers to use wearable sensors for early detection of Huntington's disease signs, focusing on gait and chorea. Led by University of Rochester’s Center for Health + Technology, the study aims to validate digital measures crucial for clinical trial outcomes, potentially impacting other neurological diseases like Parkinson's.

The ICH E6 (R3) guideline revision emphasizes enhanced sponsor oversight, stringent quality requirements, and risk-based approaches in clinical trials, fostering transparency and leveraging technology to ensure trial integrity and participant safety.

Talquetamab, a bispecific GPRC5D-directed CD3 T-cell engager, demonstrated durable responses in multiple myeloma patients with 4-5 prior therapies in TRIMM-2 and RedirecTT trials. Updated phase 1b results showed an 81.8% ORR and 15.5-month median PFS in the TRIMM-2 triplet arm, and a 79.5% ORR at 18 months in the RedirecTT-1 dual bispecific arm. Both combinations showed robust durability and efficacy, even in high-risk patients with extramedullary disease.

Alpha Tau Medical's Alpha DaRT® receives FDA approval for a multi-center study to treat recurrent cutaneous Squamous Cell Carcinoma in immunocompromised patients, led by Emory University.

Alpha Tau Medical Ltd. announced FDA approval for a multi-center study using Alpha DaRT to treat recurrent cutaneous Squamous Cell Carcinoma in immunocompromised patients. The study, led by Winship Cancer Institute of Emory University, aims to enroll up to 28 patients at 8 U.S. institutions, focusing on objective response rate, progression-free survival, and safety.

Clarivate Plc unveils Citation Laureates 2024, forecasting Nobel Prize recipients based on extraordinary citation records and societal impact. This year's 22 laureates span six countries and have made significant contributions to fields like clean energy, nanotechnology, and quantum computing.